Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 12, 2023

Long-Term Efficacy and Safety of Inclisiran in Patients With High Cardiovascular Risk and Elevated LDL-C Levels

The Lancet Diabetes & Endocrinology


Additional Info

The Lancet Diabetes & Endocrinology
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Lancet Diabetes Endocrinol 2023 Jan 05;[EPub Ahead of Print], KK Ray, RPT Troquay, FLJ Visseren, LA Leiter, R Scott Wright, S Vikarunnessa, Z Talloczy, X Zang, P Maheux, A Lesogor, U Landmesser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading